Impax Laboratories
3-year average:
Revenue Growth: 43%
Profit Growth: 85%
Total Return: 40%
Revenue Growth: 43%
Profit Growth: 85%
Total Return: 40%
Of all the companies to make it onto
this year’s Fastest-Growing list, Impax Labs has likely produced the
most volatile results. Over the past five years, net income has
fluctuated significantly from as low as $16 million in 2006 and 2008 to
as high as $250 million in 2010, and several points in between. The
self-described “technology-based speciality pharmaceutical company”
specializes in “controlled-release” generic versions of brand-name
drugs. Among its biggest sellers are migraine-treating drug Zomig, and
Adderall XR, which is used to treat attention deficit disorder. In 2010,
net income sky-rocketed 400%. Impax put this down to a one-time
accounting benefit, along with increased sales of several key products.
Last year profits came crashing down 74%, however, as global sales
declined across the board and supply disruptions affected Adderall XR. -- N.S.
No comments:
Post a Comment